Novo Nordisk Earnings Boost Stock in Ozempic Maker
Novo Nordisk stock gained, lifted by strong sales growth and guidance from the maker of Wegovy and Ozempic. Shares in Novo, one of Europe's largest listed companies, advanced nearly 3% in Denmark. Dig ...
EconoTimes2h
European Stocks Flat as Novo Nordisk Gains Offset Tech Losses
European stocks remained flat in early trading Wednesday, as gains in healthcare were counterbalanced by a decline in ...
Novo Nordisk Stock Jumps After Earnings. The Weight-Loss Drugmaker Has Growth Concerns.
The weight-loss drugmaker's Wegovy and Ozempic are among the most closely watched new medications in recent history, but face serious competition from Eli Lilly’s Zepbound and Mounjaro.
Swissinfo4h
US Stock Futures Fall as Alphabet, AMD Tumble: Markets Wrap
US equity futures dropped as investors navigate the trade war and a busy slate of earnings from some of the world’s biggest ...
Novo Nordisk sales beat estimates, but the story wasn't Ozempic
Novo Nordisk shares (DK:NOVO.B) (NVO) rallied 4% in early Copenhagen trade. Ozempic's 33.85 billion kroner of sales compared to analyst expectations of 33.34 billion kroner, and Wegovy's 19.87 billion ...
Novo Nordisk Expects Slowing Sales Growth This Year — Update
Novo Nordisk expects sales growth to slow this year as capacity constraints, intensifying competition and pricing pressure drag on sales of its blockbuster weight-loss and diabetes drugs. The Danish ...
The Armenian Reporter1d
Stock Yards Bank & Trust Co. Buys 651 Shares of Novo Nordisk A/S (NYSE:NVO)
Stock Yards Bank & Trust Co. increased its stake in Novo Nordisk A/S (NYSE:NVO – Free Report) by 16.5% during the fourth ...
The Armenian Reporter1d
Novo Nordisk A/S (NYSE:NVO) Shares Sold by Calamos Advisors LLC
Calamos Advisors LLC lessened its stake in Novo Nordisk A/S (NYSE:NVO – Free Report) by 33.4% in the fourth quarter, Holdings ...
Novo Nordisk's Guidance and Production Capacity in Focus -- Earnings Preview
--"The 2025 forecast will command the most attention in the annual accounts," Hansen said. "The addition of production capacity will continue to be the guiding principle for the full-year forecast." ...
UBS Keeps Their Buy Rating on Novo Nordisk (0QIU)
In a report released today, Jo Walton from UBS maintained a Buy rating on Novo Nordisk (0QIU – Research Report), with a price target of ...
bovnews2d
Novo Nordisk A/S (NVO) Stock: Unveiling Its Hidden Strengths
Novo Nordisk A/S (NVO) stock saw a decline, ending the day at $84.45 which represents a decrease of $-0.89 or -1.04% from the prior close of $85.34. The stock opened at $84.87 and touched a low of $84 ...
bovnews5d
Novo Nordisk A/S (NVO) Stock’s -0.04% Decrease This Year: What’s the Story?
Novo Nordisk A/S (NVO) stock saw a decline, ending the day at $84.03 which represents a decrease of $-1.16 or -1.36% from the prior close of $85.19. The stock opened at $85.62 and touched a low of $83 ...